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Bacterial resistance to antibiotics is increasing worldwide in healthcare settings and in the community. Some
microbial pathogens have become resistant to multiple antibiotics, if not all presently available, thus severely
compromising treatment success and contributing to enhanced morbidity, mortality, and resource use. The major
driver of resistance is misuse of antibiotics in both human and non-human medicine. Both enhanced access and
restricted use in many parts of the world is mandatory. There is an urgent need for an international, integrated,
multi-level action to preserve antibiotics in the armamentarium of the 21st century and address the global issue of
antimicrobial resistance.
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Antibiotics are one of the most important discoveries in
medicine and have saved millions of lives. The current
paradoxical scandal is that although most resource-
limited countries still lack easy access to antibiotics,
their overuse and abuse is rife in developed nations and
the cause of accelerating rates of resistance development.
A global two-pronged approach is urgently needed to
promote facilitated access and to alert the scientific and
lay community to the dangers of misuse, potentially
leading to a severe lack of therapeutic agents to treat
infections in the near future.
Access to antibiotics is a major concern in many coun-
tries worldwide [1-4]. Reasons include the very low eco-
nomic status of a large number of nations, inappropriate
use, the high cost of the most recent and efficacious anti-
biotics, extensive “over the counter” usage, an increasing
number of counterfeit drugs, and a dramatic increase in
antimicrobial resistance (AMR). Importantly, countries
with only a few antibiotics available and a high number of
deaths from infection are not protected from antibiotic re-
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distribution, and reproduction in any mediumeradication of some pandemic infections, such as malaria,
tuberculosis, and human immunodeficiency virus (HIV)/
acquired immunodeficiency syndrome (AIDS), in particu-
lar due to the generous support of the Global Fund,
UNITAID, The Bill & Melinda Gates Foundation, and
other large international funding organizations. However,
infections due to common microorganisms responsible for
more widely-spread diseases still represent an extremely
high overall burden worldwide, such as pneumonia,
gastrointestinal infections, and meningitis.Resistance in healthcare
Antibiotic resistance in healthcare facilities is a very se-
rious concern in most developed and developing nations.
Only a few Scandinavian countries and the Netherlands
have had the strategic vision to limit the invasion of
their country by resistant strains through the implemen-
tation of very active programmes. Somewhat ironically,
some bacteria, particularly Gram-negatives, are now re-
sistant to almost every available antibiotic, including the
most recent generation [7]. Some are still susceptible to
colistin, a 50-year-old and rather toxic compound, al-
most forgotten until recently or only used in resource-
limited countries [8]. Late-onset ventilator-associated
pneumonia is treated empirically with colistin in the
intensive care units of several countries but, unfortu-
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scenario for the future is that an unknown number of
patients might die because active antibiotics are no
longer available. This is unacceptable, although far less
unacceptable than the lack of access to antibiotics in
many countries.
Community-acquired resistance
Resistance to antibiotics in the community is an emer-
ging problem in developed and developing countries and
possibly even more frightening. The best examples are
community- acquired methicillin-resistant Staphylococcus
aureus (MRSA), particularly in the USA [10], Escherichia
coli or Klebsiella pneumonia-producing extended-spectrum
beta-lactamases (ESBL) [11] and, more recently, carbapene-
mases [12]. The risk is that carbapenems could replace
cephalosporins or broad-spectrum penicillins for the em-
piric treatment of community-acquired diseases, such as
pyelonephritis or intra-abdominal infections, where our life-
long “partners”, enterobacteriacae, are involved. Carbape-
nems are the main antibiotics that remain efficient for the
treatment of hospital-acquired ESBL infections and repre-
sent our last line of defence in many regards. Many carba-
penemases have already been described, notably in E. coli
and K. pneumonia [12], and this class of antibiotics is in real
danger and must be protected. To achieve this, carbapenem
use must be regulated and restricted to severe infections
treated with specialist input or in consultation with a clin-
ical infectious diseases’ specialist. Combinations of beta-
lactams with beta-lactamases inhibitors are likely to be
helpful in the future [13,14].
We have available a good list of new compounds highly
active against Gram-positive bacteria, but only very few
active against multi-resistant Gram-negatives in the pipe-
line. This constitutes a critical safety issue worldwide and
is certainly far more important in terms of potential
impact than the H1N1 influenza pandemic (25,000 versus
14,000, respectively, in Europe in 2009) [15,16]. The reality
is that both short- and long-term international reactions
to such a threat have been too weak and too slow. We
have been unable or unwilling to modify global behaviour
towards antibiotic use, thus preparing a very dark future
for generations to come.
Rethinking current clinical practice
In the critically ill, particularly for septic shock, recent
international guidelines strongly encourage clinicians to
start broad spectrum antibiotics immediately, if possible
within the first hour of admission [17]. In many institu-
tions, delaying the start of antibiotics to treat community-
acquired pneumonia is considered as an indicator of poor
quality of care. Such measures make sense and possibly
save lives [18]. However, the use of such indicators and
the desire to meet required targets may have unintendedconsequences or harm. Therefore, clinicians should ensure
that the diagnosis is robust to prevent unnecessary treat-
ment with broad spectrum antibiotics. All treatment
should be subject to review after two or three days and
new antibiotics should require the prior input of an infec-
tion specialist [19]. In many cases, antibiotics can be
stopped at days two or three or changed to narrower
spectrum compounds. If combination therapy has been
used empirically, subsequent reversion to monotherapy is
possible in most cases. The term “de-escalation” is
sometimes used to describe such a strategy, but there are
two prerequisites for success. First, clinicians and micro-
biologists must be encouraged to obtain appropriate
microbiological samples before starting empiric therapy to
streamline the antibiotic strategy, particularly in the critic-
ally ill. Second, clinicians need to feel comfortable about
the decision to de-escalate, even when initial therapy was
effective. The motto “don’t change a winning team” is cer-
tainly not applicable to antibiotic therapy. Microorganisms
represent very special therapeutic targets ― a living and
respectful target. Similar to many antibiotics, bacteria have
been present in the environment long before man and due
respect is essential, at least from an ecological standpoint.
In some European countries, physicians feel at ease to
change initial empiric antibiotic therapy even when it
works, thus following recommendations issued in re-
cently published guidelines [20]. Prescribers need help,
not blame. National guidelines have been elaborated
over the past few years [21,22], including for veterinary
medicine [23], as well as many reports on the prevention
of AMR spread [21,24,25]. However, since the report of
an international task force meeting in 1995 [26], no truly
coordinated, international efforts have been made to
tackle the global issue of AMR and access to antibiotics,
apart from specific diseases such as malaria, tubercu-
losis, and HIV/AIDS.
Developing a collective conscience
Limiting antibiotic consumption comprises a certain de-
gree of risk. Some diseases, such as post-streptococcal
infections could reappear. Some infections, like meningi-
tis, might be more frequent if patients with high fever
are no longer treated with antibiotics. Risks must be
evaluated, carefully followed, and balanced against the
risk of resistance. National public health agencies and
international organizations, such as the World Health
Organization (WHO), must assume their responsibility
and give clear recommendations, while taking such risks
into account. There are additional philosophical and
ecological reasons to focus on equity and access to anti-
biotics. Most antibiotics, like animals and plants, are
natural products belonging to “mother nature” and hu-
manity. Part of our collective ecological and moral duty
is not only to protect them, but also to make them
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of quality and safety [27].
AMR is considered an extremely serious issue by the
WHO Patient Safety programme. Its recent publication
entitled "The evolving threat of antimicrobial resistance -
options for action" [28] examines the experiences of
governments and health facilities/providers with imple-
menting some of the recommendations of the 2001
WHO Global Strategy for Containment of Antimicrobial
Resistance. It reflects upon lessons learned during the
past decade and remaining gaps, while drawing atten-
tion to areas where knowledge is still lacking and urgent
action needed. One of the programme strands, African
Partnerships for Patient Safety, includes the prevention
of healthcare-associated infections and access to anti-
microbials as it is clearly established that developing
countries have very high rates of nosocomial infections
and AMR [5]. The precise burden of non-access to anti-
biotics is unknown and these data are urgently needed.
If we do not undertake this global, international,
integrated action now, future generations will certainly
never forgive us for having been so weak and passive to
meet this challenge.
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